Corium International (NASDAQ:CORI) was upgraded by equities researchers at ValuEngine from a “buy” rating to a “strong-buy” rating in a report released on Friday.

Other equities research analysts have also issued research reports about the company. HC Wainwright reissued a “buy” rating and issued a $13.00 target price on shares of Corium International in a research report on Monday, August 13th. Cantor Fitzgerald reissued a “buy” rating and issued a $14.00 target price on shares of Corium International in a research report on Friday, August 10th. Zacks Investment Research raised Corium International from a “sell” rating to a “hold” rating in a research report on Tuesday, August 14th. Finally, BidaskClub raised Corium International from a “strong sell” rating to a “sell” rating in a research report on Friday, August 3rd. One analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $12.80.

Shares of Corium International stock opened at $12.70 on Friday. Corium International has a 52-week low of $7.17 and a 52-week high of $13.93. The company has a market capitalization of $344.74 million, a P/E ratio of -7.74 and a beta of 1.61. The company has a current ratio of 7.61, a quick ratio of 7.47 and a debt-to-equity ratio of 2.83.

Corium International (NASDAQ:CORI) last announced its earnings results on Thursday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.38) by $0.04. Corium International had a negative return on equity of 276.89% and a negative net margin of 155.21%. The business had revenue of $7.67 million for the quarter, compared to analyst estimates of $6.72 million. Research analysts forecast that Corium International will post -1.53 earnings per share for the current year.

In other Corium International news, insider Joseph J. Sarret sold 3,565 shares of the firm’s stock in a transaction that occurred on Friday, August 17th. The stock was sold at an average price of $9.01, for a total value of $32,120.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Parminder Singh sold 3,133 shares of the firm’s stock in a transaction that occurred on Friday, August 17th. The shares were sold at an average price of $9.01, for a total value of $28,228.33. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 119,965 shares of company stock valued at $1,060,275. Corporate insiders own 30.80% of the company’s stock.

A number of hedge funds have recently bought and sold shares of CORI. BlackRock Inc. grew its stake in Corium International by 11.9% in the first quarter. BlackRock Inc. now owns 1,880,505 shares of the biopharmaceutical company’s stock valued at $21,569,000 after purchasing an additional 200,690 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Corium International by 1,746.7% in the first quarter. JPMorgan Chase & Co. now owns 96,935 shares of the biopharmaceutical company’s stock valued at $1,112,000 after purchasing an additional 91,686 shares in the last quarter. Citadel Advisors LLC bought a new position in Corium International in the first quarter valued at approximately $455,000. Iguana Healthcare Management LLC boosted its stake in shares of Corium International by 22.2% during the 1st quarter. Iguana Healthcare Management LLC now owns 110,000 shares of the biopharmaceutical company’s stock worth $1,262,000 after acquiring an additional 20,000 shares during the period. Finally, Private Capital Advisors Inc. bought a new position in shares of Corium International during the 2nd quarter worth approximately $521,000.

About Corium International

Corium International, Inc, a biopharmaceutical company, focuses on the development, manufacture, and commercialization of specialty pharmaceutical products in transdermal and transmucosal delivery systems. It offers Clonidine Transdermal Delivery System (TDS), a treatment for hypertension; Fentanyl TDS, a treatment for the management of chronic pain, including cancer-related pain; and Crest Whitestrips for teeth whitening.

Featured Article: Earnings Per Share (EPS) Explained

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Corium International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International and related companies with MarketBeat.com's FREE daily email newsletter.